Lauren M.F. Merlo
Title
Cited by
Cited by
Year
Cancer as an evolutionary and ecological process
LMF Merlo, JW Pepper, BJ Reid, CC Maley
Nature reviews cancer 6 (12), 924-935, 2006
16602006
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma
LMF Merlo, NA Shah, X Li, PL Blount, TL Vaughan, BJ Reid, CC Maley
Cancer prevention research 3 (11), 1388-1397, 2010
1552010
IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation
R Metz, C Smith, JB DuHadaway, P Chandler, B Baban, LMF Merlo, ...
International immunology 26 (7), 357-367, 2014
1402014
Cancer in light of experimental evolution
K Sprouffske, LMF Merlo, PJ Gerrish, CC Maley, PD Sniegowski
Current Biology 22 (17), R762-R771, 2012
892012
IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis
LMF Merlo, E Pigott, JB DuHadaway, S Grabler, R Metz, GC Prendergast, ...
The Journal of Immunology 192 (5), 2082-2090, 2014
832014
IDO2 in immunomodulation and autoimmune disease
GC Prendergast, R Metz, AJ Muller, LMF Merlo, L Mandik-Nayak
Frontiers in immunology 5, 585, 2014
792014
The role of genetic diversity in cancer
LMF Merlo, CC Maley
The Journal of clinical investigation 120 (2), 401-403, 2010
712010
Polyploidy, aneuploidy and the evolution of cancer
LMF Merlo, JW Pepper, PS Rabinovitch, CC Maley
Polyploidization and Cancer, 1-13, 2010
382010
Development and characterization of an organotypic model of Barrett's esophagus
RE Kosoff, KL Gardiner, LMF Merlo, K Pavlov, AK Rustgi, CC Maley
Journal of cellular physiology 227 (6), 2654-2659, 2012
362012
Therapeutic antibody targeting of indoleamine-2, 3-dioxygenase (IDO2) inhibits autoimmune arthritis
LMF Merlo, S Grabler, JB DuHadaway, E Pigott, K Manley, ...
Clinical Immunology 179, 8-16, 2017
312017
IDO2 modulates T cell–dependent autoimmune responses through a B cell–intrinsic mechanism
LMF Merlo, JB DuHadaway, S Grabler, GC Prendergast, AJ Muller, ...
The Journal of Immunology 196 (11), 4487-4497, 2016
302016
IDO2: a pathogenic mediator of inflammatory autoimmunity
LMF Merlo, L Mandik-Nayak
Clinical Medicine Insights: Pathology 9, CPath. S39930, 2016
232016
An in vitro co-culture model of esophageal cells identifies ascorbic acid as a modulator of cell competition
LMF Merlo, RE Kosoff, KL Gardiner, CC Maley
BMC cancer 11 (1), 461, 2011
202011
An empirical test of the concomitantly variable codon hypothesis
LMF Merlo, M Lunzer, AM Dean
Proceedings of the National Academy of Sciences 104 (26), 10938-10943, 2007
132007
The argRB of Escherichia coli is rare in isolates obtained from natural sources
LMF Merlo, MJ Sadowsky, JA Ferguson, AM Dean
Gene 376 (2), 240-247, 2006
42006
Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses
LMF Merlo, JB DuHadaway, JD Montgomery, WD Peng, PJ Murray, ...
Frontiers in immunology 11, 1861, 2020
32020
Adaptive immunity: B cells and antibodies
LMF Merlo, L Mandik-Nayak
Cancer Immunotherapy, 25-40, 2013
32013
B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2, 3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model
LMF Merlo, J Bowers, T Stefanoni, R Getts, L Mandik-Nayak
Clinical Pathology 13, 2632010X20951812, 2020
12020
IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.
R Metz, C Smith, JB DuHadaway, P Chandler, B Baban, LMF Merlo, ...
International immunology 31 (3), 181-182, 2019
12019
Cancer Immunotherapy: Chapter 3. Adaptive Immunity: B Cells and Antibodies
LMF Merlo, L Mandik-Nayak
Elsevier Inc. Chapters, 2013
12013
The system can't perform the operation now. Try again later.
Articles 1–20